Gland Pharma Ltd. shares jumped 6% in morning trade following the announcement of its second-quarter fiscal 2025 results.
The company’s consolidated net profit fell 16% to Rs 163.53 crore for the quarter ending Sept. 30, 2024, meeting analysts’ expectations of Rs 162.9 crore. This marks a decrease from Rs 194.08 crore in the same period last year.
A key factor impacting profitability was the rising cost of raw materials, which increased to 39.2% of sales compared to 37.9% last year. This cost rise contributed to a drop in Gland Pharma’s EBITDA margin, which stood at 21.1%, down from 24% a year earlier.
As of 9:39 am, Gland Pharma shares were trading 5.97% higher at Rs 1,707.00 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
